HomeCompareENEKF vs JNJ

ENEKF vs JNJ: Dividend Comparison 2026

ENEKF yields 7.38% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENEKF wins by $2.3K in total portfolio value
10 years
ENEKF
ENEKF
● Live price
7.38%
Share price
$27.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.6K
Annual income
$1,177.90
Full ENEKF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ENEKF vs JNJ

📍 ENEKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENEKFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENEKF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENEKF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENEKF
Annual income on $10K today (after 15% tax)
$627.07/yr
After 10yr DRIP, annual income (after tax)
$1,001.22/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $2,984.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENEKF + JNJ for your $10,000?

ENEKF: 50%JNJ: 50%
100% JNJ50/50100% ENEKF
Portfolio after 10yr
$31.4K
Annual income
$2,933.65/yr
Blended yield
9.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ENEKF
No analyst data
Altman Z
5.5
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENEKF buys
0
JNJ buys
0
No recent congressional trades found for ENEKF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENEKFJNJ
Forward yield7.38%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$32.6K$30.3K
Annual income after 10y$1,177.90$4,689.40
Total dividends collected$9.6K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ENEKF vs JNJ ($10,000, DRIP)

YearENEKF PortfolioENEKF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,438$737.74$10,592$272.30+$846.00ENEKF
2$13,027$788.60$11,289$357.73+$1.7KENEKF
3$14,778$839.41$12,123$472.89+$2.7KENEKF
4$16,703$889.97$13,141$629.86+$3.6KENEKF
5$18,812$940.05$14,408$846.81+$4.4KENEKF
6$21,118$989.50$16,021$1,151.60+$5.1KENEKF
7$23,635$1,038.14$18,122$1,588.22+$5.5KENEKF
8$26,375$1,085.84$20,930$2,228.20+$5.4KENEKF
9$29,354$1,132.46$24,792$3,191.91+$4.6KENEKF
10$32,586$1,177.90$30,274$4,689.40+$2.3KENEKF

ENEKF vs JNJ: Complete Analysis 2026

ENEKFStock

Enea AB (publ) provides software products for telecommunication, cybersecurity, medical device, and aerospace industries worldwide. It offers 5G data management products, such as Enea Stratum Network Data Layer, Enea Unified Data Manager, Enea Digital Identity, and Enea Equipment Identity Register; and access management and policy control services, including Enea Access Manager, Enea Policy Manager, and Enea ENUM. The company also provides traffic management services comprising Enea Video Optimization, Enea DPI and Content Filtering, Enea Integra NFV Platform, Encrypted Video Management, Enea TCP Acceleration, Enea Traffic Classifier, and Enea IP Traffic Filtering; and Enea Edge, a virtualization and management platform designed for deployment on any white-box uCPE, and optimized for common uCPE networking and edge use cases, such as SD-WAN, security, IoT, and 5G. In addition, the company offers Qosmos ixEngine, a deep packet inspection software; Qosmos Probe, a network sensor for granular visibility into network activity; Aptilo SMP Venue Wi-Fi Manager; and Zero-touch Wi-Fi IoT and Cellular IoT Connectivity services. Further, it provides Enea OSE, a real-time operating system for multi-processor systems; Enea Linux, a carrier-grade Linux for networking and real-time applications; and Enea OSEck, an operating system for high-performance and memory constrained applications. Additionally, it offers Enea Netbricks, a collection of highly portable networking protocols; Enea Element High Availability, an application development framework that simplifies the design and implementation of applications; and Enea Polyhedra, a SQL database, as well as software development and training services. Enea AB (publ) was founded in 1968 and is headquartered in Kista, Sweden.

Full ENEKF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ENEKF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENEKF vs SCHDENEKF vs JEPIENEKF vs OENEKF vs KOENEKF vs MAINENEKF vs ABBVENEKF vs MRKENEKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.